Solifenacin
Solifenacin, Vesicare (solifenacin) is a small molecule pharmaceutical. Solifenacin was first approved as Vesicare on 2004-11-19. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M3 and muscarinic acetylcholine receptor M2. In addition, it is known to target muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M5, and muscarinic acetylcholine receptor M1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Solifenacin, Vesicare (discontinued: Solifenacin, Vesicare)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Solifenacin succinate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VESICARE | Astellas Pharma | N-021518 RX | 2004-11-19 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| solifenacin succinate | ANDA | 2025-09-30 |
| solifenacin succinate solifenacin succinate | ANDA | 2021-11-22 |
| solifenacine succinate | ANDA | 2022-12-05 |
| vesicare | New Drug Application | 2022-10-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| overactive urinary bladder | EFO_1000781 | D053201 | N32.81 |
| urge urinary incontinence | EFO_0006865 | D053202 | N39.41 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Solifenacin Succinate, Vesicare Ls, Astellas | |||
| 9918970 | 2031-05-18 | DP | |
ATC Codes
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04B: Urologicals
— G04BD: Drugs for urinary frequency and incontinence
— G04BD08: Solifenacin
— G04C: Drugs used in benign prostatic hypertrophy
— G04CA: Alpha-adrenoreceptor antagonists, benign prostatic hypertrophy
— G04CA53: Tamsulosin and solifenacin
HCPCS
No data
Clinical
Clinical Trials
164 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 3 | 2 | 16 | 20 | 7 | 48 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | 1 | 2 | 2 | 3 | 2 | 10 |
| Urinary incontinence | D014549 | — | R32 | 1 | — | 1 | 5 | 2 | 9 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 1 | 1 | 2 | 3 | — | 7 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | — | 3 | 3 | — | 6 |
| Enuresis | D004775 | — | R32 | — | — | — | 3 | 1 | 4 |
| Stress urinary incontinence | D014550 | — | — | — | — | — | 2 | — | 2 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | 1 | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | 1 | — | 1 |
| Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | — | — | 1 | — | 1 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urologic diseases | D014570 | — | N39.9 | — | 1 | 4 | — | — | 5 |
| Urinary bladder diseases | D001745 | — | N32.9 | — | 1 | 4 | — | — | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary bladder neck obstruction | D001748 | EFO_1000840 | N32.0 | 1 | 1 | — | — | — | 2 |
| Signs and symptoms | D012816 | EFO_0003765 | R68 | — | 1 | — | — | — | 1 |
| Urological manifestations | D020924 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 11 | — | — | — | — | 11 |
| Pharmacokinetics | D010599 | — | — | 5 | — | — | — | — | 5 |
| Drug interactions | D004347 | — | — | 3 | — | — | — | — | 3 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Solifenacin |
| INN | solifenacin |
| Description | Solifenacin is a member of isoquinolines. |
| Classification | Small molecule |
| Drug class | muscarinic receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 242478-37-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1734 |
| ChEBI ID | — |
| PubChem CID | 154059 |
| DrugBank | DB01591 |
| UNII ID | A8910SQJ1U (ChemIDplus, GSRS) |
Target
Agency Approved
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Solifenacin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,054 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,855 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use